A Study to Evaluate the DDI of DBPR108 With Metformin,Glibenclamide,Valsartan, or Simvastatin in Healthy Subjects

NCT ID: NCT04859452

Last Updated: 2021-07-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 56 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-05-26
• Study Completion Date: 2021-07-09

Brief Summary

This is a four-part, single-center, open-label, single-sequence crossover phase I clinical study to characterize the Drug-Drug Interaction (DDI) potential of DBPR108 at steady-state with Metformin hydrochloride, Glibenclamide, Valsartan, or Simvastatin in Healthy Subjects. This study also aims to evaluate the safety and tolerability of DBPR108 in the presence of Metformin hydrochloride, Glibenclamide, Valsartan, or Simvastatin.

Detailed Description

DBPR108 is a potent dipeptidylpeptidase-4 inhibitor. This study will be run in four parts to characterize the Drug-Drug Interaction (DDI) potential of DBPR108 with the expected concomitant drugs (Metformin hydrochloride, Glibenclamide, Valsartan, Simvastatin) in Healthy Subjects. Each part of this study consists of a screening period (Day -14 to Day -1), a baseline period (Day -1), a treatment period (Day 1 to Day 9), and a follow-up visit on Day 15. Approximately 14 subjects will be enrolled in each part of this study.

Conditions

Healthy Subjects

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

The DDI of DBPR108 tablets and Metformin hydrochloride tablets

Subjects will receive a single dose of metformin hydrochloride on Day 1, then take once-daily DBPR108 100 mg on Day 4 through Day 8 and a single dose of metformin hydrochloride on Day 8.

Group Type: EXPERIMENTAL

DBPR108 tablets

Intervention Type: DRUG

Drug: DBPR108, tablet, oral

Metformin hydrochloride tablets

Intervention Type: DRUG

Drug: Metformin hydrochloride, tablet, oral

The DDI of DBPR108 tablets and Glibenclamide tablets

Subjects will receive a single dose of Glibenclamide on Day 1, then take once-daily DBPR108 100 mg on Day 4 through Day 8 and a single dose of Glibenclamide on Day 8.

Group Type: EXPERIMENTAL

DBPR108 tablets

Intervention Type: DRUG

Drug: DBPR108, tablet, oral

Glibenclamide tablets

Intervention Type: DRUG

Drug: Glibenclamide, tablet, oral

The DDI of DBPR108 tablets and Valsartan Capsules

Subjects will receive a single dose of Valsartan on Day 1, then take once-daily DBPR108 100 mg on Day 4 through Day 8 and a single dose of Valsartan on Day 8.

Group Type: EXPERIMENTAL

DBPR108 tablets

Intervention Type: DRUG

Drug: DBPR108, tablet, oral

Valsartan Capsules

Intervention Type: DRUG

Drug: Valsartan, capsule, oral

The DDI of DBPR108 tablets and Simvastatin tablets

Subjects will receive a single dose of Simvastatin on Day 1, then take once-daily DBPR108 100 mg on Day 4 through Day 8 and a single dose of Simvastatin on Day 8.

Group Type: EXPERIMENTAL

DBPR108 tablets

Intervention Type: DRUG

Drug: DBPR108, tablet, oral

Simvastatin tablets

Intervention Type: DRUG

Drug: Simvastatin, tablet, oral

Interventions

DBPR108 tablets

Drug: DBPR108, tablet, oral

Intervention Type: DRUG

Metformin hydrochloride tablets

Drug: Metformin hydrochloride, tablet, oral

Intervention Type: DRUG

Glibenclamide tablets

Drug: Glibenclamide, tablet, oral

Intervention Type: DRUG

Valsartan Capsules

Drug: Valsartan, capsule, oral

Intervention Type: DRUG

Simvastatin tablets

Drug: Simvastatin, tablet, oral

Intervention Type: DRUG

Other Intervention Names

DBPR108

Eligibility Criteria

Inclusion Criteria

• Voluntarily sign the informed consent form, understand the trial procedures, and be willing to comply with all trial procedures and restrictions；
• 18 years to 45 years (inclusive), male or female；
• Male subjects weight ≥50 kg and female subjects weight ≥45 kg. Body mass index (BMI) : 18-30 kg/m2 (inclusive) (BMI= weight (kg)/height 2 (m2))；
• Subjects (including partners) are willing to use effective contraceptives from screening to the 6 months after the last dose administration；
• Be judged to be in good health by the investigator, based on the physical examination, vital sign examination, 12-lead electrocardiogram (ECG) examination and laboratory examination；

Exclusion Criteria

• Subjects who have a history of allergic conditions (such as asthma, urticaria), or have a history of allergy to two or more drugs or food, or may be allergic to the test drug and the related compounds;
• Have a history of severe diseases, such as cardiovascular, respiratory, liver, gastrointestinal, endocrine, hematologic, mental/nervous systems diseases within 1 year prior to screening；
• Subjects who have previously undergone surgery that may affect drug absorption, distribution, metabolism, or excretion (e.g., subtotal gastrectomy), or who have a scheduled surgical plan during the study period;
• Use of any prescription drug, over-the-counter drug, or herbal medicine within 2 weeks prior to screening;
• Drug abuse, or positive urine drug screen at screening；
• Smoking more than 5 cigarettes per day within 3 months prior to screening；
• Average alcohol intake is more than 28g alcohol (male) or 14g (female) per week (14g ≈ 497mL beer, or 44mL spirits with low alcohol content, or 145mL wine) within the 3 months prior to screening, or taking any alcohol within 48 hours before dosing, or a positive ethanol breath test at screening；
• Consumption of grapefruit juice, Methylxanthine-rich food or beverage (such as coffee, tea, cola, chocolate, energy drinks) within 48 hours before the administration, or have strenuous exercise, or have other factors affecting drug absorption, distribution, metabolism, excretion, etc；
• Participation in another clinical trial within 3 months before screening；
• Blood donation (or blood loss) ≥400 mL, or receiving whole blood transfusions or erythrocyte suspension transfusions within 3 months prior to the screening；
• The patients who have undergone comprehensive inspection with any significant clinical significant in physical examination (vital signs, physical examination), routine laboratory examination (blood routine, blood biochemical examination, urine routine), chest X-ray (anteroposterior), abdominal B (liver, bile, pancreas, spleen and kidney) and other examinations, as judged by the investigator;
• Have a positive test result of hepatitis B surface antigen, hepatitis C antibody, anti-human immunodeficiency virus antibody or anti-Treponema pallidum specific antibody;
• A pregnant/lactating woman, or has a positive pregnancy test at screening or during the trial.；
• Not suitable for this study as judged by the investigator；

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

First Affiliated Hospital of Soochow University

Suzhou, , China

Countries

China

Other Identifiers

HA1118-CSP-010

Identifier Type: -

Identifier Source: org_study_id